Single-Cell-Derived Malignant Epithelial Programs Define Prognostic Risk and Therapeutic Vulnerability in Ovarian Cancer.

IF 3.4 3区 医学 Q2 ONCOLOGY
Journal of Cancer Pub Date : 2026-07-03 eCollection Date: 2026-01-01 DOI:10.7150/jca.135548
Jingwen Si, Hanbo Li, Han Zhang, Yan Shen
{"title":"Single-Cell-Derived Malignant Epithelial Programs Define Prognostic Risk and Therapeutic Vulnerability in Ovarian Cancer.","authors":"Jingwen Si, Hanbo Li, Han Zhang, Yan Shen","doi":"10.7150/jca.135548","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Ovarian cancer (OV) is characterized by pronounced intratumoral heterogeneity and unfavorable clinical outcomes, yet clinically applicable biomarkers for risk stratification remain limited. Although bulk transcriptomic models have been widely proposed, they often overlook the cellular origins of prognostic signals. Advances in single-cell RNA sequencing (scRNA-seq) provide an opportunity to resolve malignant epithelial diversity and identify biologically meaningful predictors.</p><p><strong>Methods: </strong>Single-cell transcriptomic datasets were integrated to construct a comprehensive epithelial landscape of OV. Copy number variation profiles inferred by inferCNV were used to distinguish malignant epithelial cells, followed by subpopulation identification and trajectory inference using Slingshot and Monocle3. Subcluster-specific gene signatures were projected onto bulk RNA-seq cohorts, and prognostic genes were screened using Cox regression and LASSO modeling to establish a multigene risk score. The model was validated across multiple independent cohorts. Multi-omics analyses, including pathway enrichment, mutational profiling, tumor mutation burden, immune features, and drug sensitivity prediction, were performed to explore biological and clinical relevance. Functional assays were conducted to validate the role of the key gene PSMB1.</p><p><strong>Results: </strong>Malignant epithelial cells exhibited substantial transcriptional heterogeneity and distinct evolutionary trajectories, revealing subpopulations associated with differential clinical outcomes. A nine-gene risk model derived from these subpopulations demonstrated robust and consistent prognostic performance across multiple datasets. The risk score was closely associated with tumor progression pathways, immune suppression, genomic instability, and reduced therapeutic sensitivity. Notably, PSMB1 was identified as a critical oncogenic factor, and its knockdown significantly inhibited proliferation and colony formation in OV cells.</p><p><strong>Conclusions: </strong>This study establishes a single-cell-informed prognostic framework that links malignant epithelial heterogeneity to clinical outcomes and therapeutic response in OV. The proposed model provides biologically interpretable risk stratification and highlights PSMB1 as a potential therapeutic target, offering new insights for precision oncology.</p>","PeriodicalId":15183,"journal":{"name":"Journal of Cancer","volume":"17 7","pages":"1274-1294"},"PeriodicalIF":3.4000,"publicationDate":"2026-07-03","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC13410796/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Journal of Cancer","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.7150/jca.135548","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2026/1/1 0:00:00","PubModel":"eCollection","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Ovarian cancer (OV) is characterized by pronounced intratumoral heterogeneity and unfavorable clinical outcomes, yet clinically applicable biomarkers for risk stratification remain limited. Although bulk transcriptomic models have been widely proposed, they often overlook the cellular origins of prognostic signals. Advances in single-cell RNA sequencing (scRNA-seq) provide an opportunity to resolve malignant epithelial diversity and identify biologically meaningful predictors.

Methods: Single-cell transcriptomic datasets were integrated to construct a comprehensive epithelial landscape of OV. Copy number variation profiles inferred by inferCNV were used to distinguish malignant epithelial cells, followed by subpopulation identification and trajectory inference using Slingshot and Monocle3. Subcluster-specific gene signatures were projected onto bulk RNA-seq cohorts, and prognostic genes were screened using Cox regression and LASSO modeling to establish a multigene risk score. The model was validated across multiple independent cohorts. Multi-omics analyses, including pathway enrichment, mutational profiling, tumor mutation burden, immune features, and drug sensitivity prediction, were performed to explore biological and clinical relevance. Functional assays were conducted to validate the role of the key gene PSMB1.

Results: Malignant epithelial cells exhibited substantial transcriptional heterogeneity and distinct evolutionary trajectories, revealing subpopulations associated with differential clinical outcomes. A nine-gene risk model derived from these subpopulations demonstrated robust and consistent prognostic performance across multiple datasets. The risk score was closely associated with tumor progression pathways, immune suppression, genomic instability, and reduced therapeutic sensitivity. Notably, PSMB1 was identified as a critical oncogenic factor, and its knockdown significantly inhibited proliferation and colony formation in OV cells.

Conclusions: This study establishes a single-cell-informed prognostic framework that links malignant epithelial heterogeneity to clinical outcomes and therapeutic response in OV. The proposed model provides biologically interpretable risk stratification and highlights PSMB1 as a potential therapeutic target, offering new insights for precision oncology.

单细胞衍生恶性上皮程序定义卵巢癌的预后风险和治疗脆弱性。
背景:卵巢癌(OV)具有明显的肿瘤内异质性和不利的临床结果,但临床适用的风险分层生物标志物仍然有限。尽管大量转录组学模型已被广泛提出,但它们往往忽略了预后信号的细胞起源。单细胞RNA测序(scRNA-seq)的进展为解决恶性上皮多样性和识别生物学上有意义的预测因子提供了机会。方法:整合单细胞转录组数据,构建OV的综合上皮景观。利用intercnv推断的拷贝数变异谱来区分恶性上皮细胞,然后利用Slingshot和Monocle3进行亚群鉴定和轨迹推断。将亚簇特异性基因特征投射到大量RNA-seq队列中,并使用Cox回归和LASSO模型筛选预后基因,以建立多基因风险评分。该模型在多个独立队列中得到验证。通过多组学分析,包括途径富集、突变谱、肿瘤突变负担、免疫特征和药物敏感性预测,探索生物学和临床相关性。功能分析验证了关键基因PSMB1的作用。结果:恶性上皮细胞表现出显著的转录异质性和独特的进化轨迹,揭示了与不同临床结果相关的亚群。来自这些亚群的九基因风险模型在多个数据集上显示出稳健和一致的预后表现。风险评分与肿瘤进展途径、免疫抑制、基因组不稳定性和治疗敏感性降低密切相关。值得注意的是,PSMB1被鉴定为一个关键的致癌因子,其敲低可显著抑制OV细胞的增殖和集落形成。结论:本研究建立了一个单细胞预后框架,将恶性上皮异质性与OV的临床结果和治疗反应联系起来。该模型提供了生物学上可解释的风险分层,并强调PSMB1是潜在的治疗靶点,为精确肿瘤学提供了新的见解。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Journal of Cancer
Journal of Cancer ONCOLOGY-
CiteScore
8.10
自引率
2.60%
发文量
333
审稿时长
12 weeks
期刊介绍: Journal of Cancer is an open access, peer-reviewed journal with broad scope covering all areas of cancer research, especially novel concepts, new methods, new regimens, new therapeutic agents, and alternative approaches for early detection and intervention of cancer. The Journal is supported by an international editorial board consisting of a distinguished team of cancer researchers. Journal of Cancer aims at rapid publication of high quality results in cancer research while maintaining rigorous peer-review process.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信
小红书